UBS Group’s Loncar China BioPharma ETF CHNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-252
| Closed | -$4.73K | – | 11012 |
|
|
2022
Q4 | $4.73K | Sell |
252
-859
| -77% | -$14.4K | ﹤0.01% | 9289 |
|
|
2022
Q3 | $16K | Sell |
1,111
-512
| -32% | -$9.1K | ﹤0.01% | 7740 |
|
|
2022
Q2 | $32K | Buy |
1,623
+806
| +99% | +$14.9K | ﹤0.01% | 6342 |
|
|
2022
Q1 | $17K | Sell |
817
-278
| -25% | -$6.16K | ﹤0.01% | 7691 |
|
|
2021
Q4 | $29K | Buy |
1,095
+141
| +15% | +$4.63K | ﹤0.01% | 7439 |
|
|
2021
Q3 | $36K | Buy |
+954
| New | +$38.9K | ﹤0.01% | 6604 |
|
|
2021
Q2 | – | Sell |
-1,681
| Closed | -$62K | – | 10005 |
|
|
2021
Q1 | $62K | Buy |
1,681
+1,291
| +331% | +$48.1K | ﹤0.01% | 6346 |
|
|
2020
Q4 | $13K | Sell |
390
-494
| -56% | -$15.1K | ﹤0.01% | 7300 |
|
|
2020
Q3 | $27K | Buy |
884
+541
| +158% | +$17.1K | ﹤0.01% | 6084 |
|
|
2020
Q2 | $11K | Sell |
343
-805
| -70% | -$21.4K | ﹤0.01% | 6968 |
|
|
2020
Q1 | $26K | Buy |
1,148
+416
| +57% | +$10.3K | ﹤0.01% | 6338 |
|
|
2019
Q4 | $18K | Buy |
+732
| New | +$17.4K | ﹤0.01% | 6953 |
|
|
2018
Q4 | – | Sell |
-436
| Closed | -$10K | – | 8398 |
|
|
2018
Q3 | $10K | Buy |
+436
| New | +$10.4K | ﹤0.01% | 7184 |
|
Other funds holding CHNA
UBS Group's CHNA Position: Q1 2023 in Review
UBS Group sold out of Loncar China BioPharma ETF (CHNA) in Q1 2023, closing a stake of 252 shares — an estimated $4.73K sold.
UBS Group first reported a position in CHNA in Q3 2018 and held it in 13 quarters. The position peaked at $62K in Q1 2021. 3 funds tracked by Wall St. Rank hold CHNA as of Q1 2023.
- UBS Group reported no remaining Loncar China BioPharma ETF position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 252 Loncar China BioPharma ETF shares in Q1 2023, an estimated $4.73K.
- UBS Group first reported a position in Loncar China BioPharma ETF in Q3 2018 and held it in 13 quarters.
- UBS Group's Loncar China BioPharma ETF position peaked at $62K in Q1 2021.
- 3 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.